2024-07-09 07:06:25 ET
Summary
- 2seventy bio, Inc. focuses on Abecma, an FDA-approved CAR T cell therapy for multiple myeloma.
- TSVT's strategic realignment includes selling non-core assets to Regeneron and Novo Nordisk.
- Abecma shows favorable clinical data but faces strong competition from Carvykti.
- I estimate that TSVT’s turnaround could lead to a positive EBIT by 2025, benefiting from significant cost-saving measures.
- TSVT's relatively cheap valuation, potential acquisition target status, and Abecma's market niche make it a compelling investment opportunity.
Read the full article on Seeking Alpha
For further details see:
2seventy bio's Abecma: Compelling Investment In Multiple Myeloma Despite Competition